"compulsory licensing" |

Compulsory Licensing– A Double Edged Sword

May 23, 2019 - 9:52 am Categories: Uncategorized

Licensing of a protected innovation or property implies permission or authority granted by the inventor or the protection holder to a third party to make use of their invention on pre-established terms. There can be a number of reasons for which a patent holder will opt to license their invention, for instance, in case the … Continue reading Compulsory Licensing– A Double Edged Sword

Pharmaceutical Patents a Threat to India’s Drug Industry?

February 14, 2018 - 12:25 pm Categories: India

0 Comments

The Indian Pharmaceutical industry is one of the largest, ranked fourth in the world in respect to the production volume. Over the last three decades, the industry’s growth has resulted from no existence to a world leader in terms of production of high quality generic drugs. Prior to 2005, no patent was granted on medicines … Continue reading Pharmaceutical Patents a Threat to India’s Drug Industry?

Compulsory Licensing: An Indian Overview

November 22, 2017 - 5:04 am Categories: Intellectual Property IP Licensing News & Updates

0 Comments

Compulsory licenses are sovereign state authorizations that enable a third party to make, use, or sell a patented product without the consent of the patent holder. Provisions pertaining to compulsory licensing are provided for under both the Indian Patent Act, 1970, as well as the international legal agreement between all the member nations of WTO … Continue reading Compulsory Licensing: An Indian Overview

Compulsory Licensing Application against the Patented Drug SAXAGLIPTIN by Lee Pharma

July 27, 2015 - 5:47 am Categories: India IP Practice in India News & Updates Patents pharma

0 Comments

Lee Pharma, a Hyderabad based Indian pharma company, has filed a Compulsory Licensing (CL) Application (in accordance with Section 84(1) of the Indian Patents Act) against one of the patented drug Saxagliptin for treating Diabetes Mellitus. The Patent on Saxagliptin was granted to Bristol Myers Squibb (BMS) in India on 30th April 2007 having number … Continue reading Compulsory Licensing Application against the Patented Drug SAXAGLIPTIN by Lee Pharma

Practice of Patent Asserting Entities: Boon or Bane: Global Innovations

October 20, 2014 - 8:55 am Categories: patent infringement Patent Litigation Patents

0 Comments

Introduction Patent troll relates to a person or company that enforces its patents against one or more alleged infringers in an opportunistic and unduly aggressive manner, often with no intention to manufacture or market the patented invention. Various terms such as patent trolls, patent monetization companies, or patent assertion entities are used for such entities; … Continue reading Practice of Patent Asserting Entities: Boon or Bane: Global Innovations

NATCO FILES INDIA’S FIRST COMPULSORY LICENSING APPLICATION

September 14, 2011 - 4:38 am Categories: Patent Commercialisation Pharma- biotech- Patent Commercialisation

0 Comments

Natco Pharma has filed India’s first Compulsory Licensing (CL) Application (in accordance with Section 84(1) of the Indian Patents Act) against one of the Bayer’s patented drug Sorafenib, marketed by Bayer as Nexavar for treating Kidney and Liver Cancer. Patent on Sorafenib is granted in India on 03.03.2008 having number IN 215758. This will be … Continue reading NATCO FILES INDIA’S FIRST COMPULSORY LICENSING APPLICATION

Tag: “compulsory licensing”

Compulsory Licensing– A Double Edged Sword

Pharmaceutical Patents a Threat to India’s Drug Industry?

Compulsory Licensing: An Indian Overview

Compulsory Licensing Application against the Patented Drug SAXAGLIPTIN by Lee Pharma

Practice of Patent Asserting Entities: Boon or Bane: Global Innovations

NATCO FILES INDIA’S FIRST COMPULSORY LICENSING APPLICATION

Categories

Archives